Peripheral Neuropathies power point one

drsudhakarlakavath 84 views 54 slides Aug 31, 2024
Slide 1
Slide 1 of 54
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54

About This Presentation

Peripheral Neuropathies power point
For under graduate students


Slide Content

Peripheral Neuropathies in Older Adults Annabel K. Wang, MD University of California, Irvine Department of Neurology

Peripheral Neuropathies Common disorder Prevalence of non-traumatic peripheral neuropathies 2.4% in general population 15% over the age of 40

Peripheral Neuropathies Terms are confusing polyneuropathy neuropathy

Peripheral Neuropathies Motor neuron disorders Radiculopathies Plexopathies Single and Multiple Mononeuropathies Symmetric Polyneuropathies Motor Neuropathies Sensory Ganglionopathies

Goals Early Recognition Early Treatment Prevention of Complications

Objectives Review symptoms and signs Identify common causes Discuss treatment options Address co-morbidities

Symptoms Positive or negative phenomena Sensory symptoms early Typically symmetric in onset Weakness later Distal symptoms predominant Worse at night

Positive Phenomena Tingling Coldness Burning Electrical shocks Stabbing sensations Deep aching

Negative phenomena Lack of sensation Hypersensitivity

Associated Symptoms Imbalance Fatigue Falls

Early Signs Distal sensory loss: Large Fibers loss of vibration before proprioception decreased ankle reflexes Small fibers Loss of pinprick and temperature Stocking-glove distribution

Early Signs Distal weakness Toe extensors Foot dorsiflexors Finger extensors

Common Causes Diabetes Leprosy Vitamin B12 deficiency

Diabetes Prevalence of Diabetes (2011): 8.3% of population 25.8 million children and adults in the US Age 65 years or older 10.9 million, or 26.9% of this age group have diabetes

Diabetes 60-70% will develop neuropathy polyneuropathy, autonomic neuropathy, CTS Association with amputation major contributor of amputations 60% of non-traumatic amputations 65,700 amputations from 2006

Diabetic Polyneuropathy Defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes An absence of symptoms should never be assumed to indicate an absence of signs

Diabetic Polyneuropathy Treatment Glucose control Pain management Management of autonomic symptoms

Leprosy Rare in United States Endemic areas Often sensory (ulnar and peroneal nerves) Associated skin lesions Hypertrophic nerves Nerve biopsy Treat underlying infection

Vitamin B12 Deficiency Prevalence: 5-20% Malabsorption, insufficient intake, pernicious anemia, gastric bypass surgery, medications Distal sensory and motor loss Combined subacute degeneration Vitamin B12 (<260 pmol/L) and methylmalonic acid (271 nmol/L) levels Supplementation: intramuscular or oral

Approach Acute vs. chronic onset Acute fulminant and live threatening Axonal vs. demyelinating Demyelinating forms respond well to immunotherapy

Acute Polyneuropathies Guillain-Barre Syndrome or Acute Inflammatory Demyelinating Polyradiculoneuropathy Porphyria Toxic (arsenic and thallium)

Chronic Polyneuropathies Inherited (CMT, HMSN, HNPP) Family History Foot Deformities Foot Ulcers Acquired “MINI”

Acquired Polyneuropathy “MINI” Metabolic Immune Neoplastic Infectious

Metabolic Causes Diabetes Uremia Alcohol abuse Hypothyroid Vitamin B1 or B12 deficiency Vitamin B6 toxicity Medications/chemotherapy

Immune Causes Vasculitis Non-vasculitic CIDP MMN Sarcoid Sjogren’s

Neoplastic Causes Paraneoplastic Paraproteinemic

MGUS M onoclonal g ammopathy of u nclear s ignificance Prevalence: 3% of persons >50 years 5% >70 years 1% per year risk of progression to multiple myeloma (MM) or a related disorder

Infectious Causes Leprosy Hepatitis C Lyme HIV West Nile Syphilis Diptheria

Autonomic Symptoms Lightheadedness or “dizziness” Blurred vision Dry eyes, dry mouth Cold feet Early satiety, constipation, diarrhea Urinary retention, incontinence Erectile Dysfunction Hypohidrosis

Dysautonomias Diabetes Amyloidosis (acquired and inherited) Paraneoplastic Inherited (HSAN) Sjogren’s Neuropathy Porphyria

Differential Diagnosis Small fiber neuropathy Plantar fasciitis Osteoarthritis Vascular insufficiency Cervical myelopathy Lumbosacral radiculopathy

Neurophysiology Electromyography Autonomic Testing Quantitative Sensory Studies

Electromyography (EMG) Two part test: Nerve conduction studies Needle electromyography Establish diagnosis of polyneuropathy Distinguish demyelinating from axonal Differentiate radiculopathy, plexopathy Normal in small fiber and autonomic neuropathy

Autonomic Testing Heart rate response to deep breathing Valsalva Maneuver Tilt Table Quantitative Sudomotor Axon Reflex Test

Basic Laboratory Investigation Hematology : complete blood count erythrocyte sedimentation rate C-reactive protein vitamin B12, folate, Methylmalonic acid, homocysteine

Basic Laboratory Investigation Biochemical and endocrine : comprehensive metabolic panel (fasting glucose) thyroid function tests serum immunofixation. glucose tolerance test if indicated

Basic Laboratory Investigation Urine: urinalysis urine immunofixation. Drugs and toxins

Specialized Laboratory Investigation Malignancies: skeletal radiographic survey mammography computed tomography or magnetic resonance imaging of chest, abdomen, and pelvis ultrasound of abdomen and pelvis positron emission tomography cerebrospinal fluid analysis including cytology serum paraneoplastic antibody profile

Specialized Laboratory Investigation Connective tissue diseases and vasculitis : antinuclear antigen profile rheumatoid factor anti-Ro/SSA, anti-La/SSB, antineutrophil cytoplasmic antigen antibody (ANCA) profile cryoglobulins.

Specialized Laboratory Investigation Infectious agents: Campylobacter jejuni Cytomegalovirus hepatitis panel (B and C) HIV Lyme disease herpes viruses West Nile virus cerebrospinal fluid analysis.

Biopsy Nerve biopsy Sural Superficial peroneal Epidermal skin biopsy

Nerve Biopsy Vasculitis Lymphoma Amyloid Sarcoid Leprosy Inflammation

Management Care of feet Inspect feet daily (mirror) Keep feet clean and moisturized Foot care with podiatrist Molded shoes Avoid walking barefoot Checking temperatures of water/sand

Treatment Foot care Physical Therapy Gait and balance exercises Ankle supports (orthotics) Occupational Therapy (ADLs)

Therapeutic Treatment Importance of diagnosis Recognition of the underlying cause Glucose control Thyroid medication Vitamin supplementation or reduction Antibiotics or antiviral medications Immunotherapy

Symptomatic Treatment Only 2 medications are FDA approved for diabetic polyneuropathy Duloxetine pregabalin

Symptomatic Treatment Pain management limited by side effects Analgesics Anti-inflammatories Antiepileptics Antidepressants Narcotics

Co-morbidities Depression Decreased mobility Falls Fear of falls Social isolation Osteoporosis

Complications Risk of injury due to lack of sensation Charcot joints Foot ulcers Amputations Falls

Summary Common disorder >40 years of age: 15% Routine screening for diabetes, vitamin B12 deficiency, serum immunofixation.

Summary Neurophysiological tests distinguish axonal /demyelinating/autonomic/small fiber Demyelinating neuropathies are commonly inflammatory and treatable. Axonal neuropathies have multiple causes

Summary Treatment Therapeutic Symptomatic Comorbidities
Tags